1. Home
  2. OCGN vs AMCX Comparison

OCGN vs AMCX Comparison

Compare OCGN & AMCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCGN
  • AMCX
  • Stock Information
  • Founded
  • OCGN 2013
  • AMCX 1980
  • Country
  • OCGN United States
  • AMCX United States
  • Employees
  • OCGN N/A
  • AMCX N/A
  • Industry
  • OCGN Biotechnology: Biological Products (No Diagnostic Substances)
  • AMCX Cable & Other Pay Television Services
  • Sector
  • OCGN Health Care
  • AMCX Telecommunications
  • Exchange
  • OCGN Nasdaq
  • AMCX Nasdaq
  • Market Cap
  • OCGN 283.3M
  • AMCX 292.9M
  • IPO Year
  • OCGN N/A
  • AMCX 2011
  • Fundamental
  • Price
  • OCGN $1.05
  • AMCX $7.10
  • Analyst Decision
  • OCGN Strong Buy
  • AMCX Sell
  • Analyst Count
  • OCGN 3
  • AMCX 5
  • Target Price
  • OCGN $6.00
  • AMCX $6.50
  • AVG Volume (30 Days)
  • OCGN 2.6M
  • AMCX 815.8K
  • Earning Date
  • OCGN 08-01-2025
  • AMCX 08-08-2025
  • Dividend Yield
  • OCGN N/A
  • AMCX N/A
  • EPS Growth
  • OCGN N/A
  • AMCX N/A
  • EPS
  • OCGN N/A
  • AMCX N/A
  • Revenue
  • OCGN $4,754,000.00
  • AMCX $2,354,176,000.00
  • Revenue This Year
  • OCGN N/A
  • AMCX N/A
  • Revenue Next Year
  • OCGN N/A
  • AMCX N/A
  • P/E Ratio
  • OCGN N/A
  • AMCX N/A
  • Revenue Growth
  • OCGN N/A
  • AMCX N/A
  • 52 Week Low
  • OCGN $0.52
  • AMCX $5.41
  • 52 Week High
  • OCGN $1.40
  • AMCX $10.72
  • Technical
  • Relative Strength Index (RSI)
  • OCGN 53.85
  • AMCX 65.81
  • Support Level
  • OCGN $1.01
  • AMCX $5.68
  • Resistance Level
  • OCGN $1.07
  • AMCX $7.33
  • Average True Range (ATR)
  • OCGN 0.05
  • AMCX 0.47
  • MACD
  • OCGN 0.00
  • AMCX 0.13
  • Stochastic Oscillator
  • OCGN 66.48
  • AMCX 61.01

About OCGN Ocugen Inc.

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

About AMCX AMC Networks Inc.

AMC Networks owns several linear pay-TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network, reached 60 million pay-TV households in the US at the end of 2024. The firm also had nearly 12.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.

Share on Social Networks: